{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-262375","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2022-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.654691+00:00","generated_at":"2026-06-23T03:35:20.832045+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"low","headline":"Imara and Enliven hold investor call on definitive merger; Enliven to become wholly owned subsidiary","bullets":["Merger agreement provides for Enliven to survive as wholly owned subsidiary of Imara via a reverse merger.","Joint investor conference call held on October 13, 2022 to discuss the transaction and its rationale.","No deal value, premium, or expected close date disclosed in this filing or the appended transcript excerpt."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-262375","json":"https://secwatch.observer/filing/0001193125-22-262375.json","markdown":"https://secwatch.observer/filing/0001193125-22-262375.md","text":"https://secwatch.observer/filing/0001193125-22-262375.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312522262375/0001193125-22-262375-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312522262375/d397742d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T03:35:20.832045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}